Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome

American Journal of Hematology

Volumn 68, Issue 4, 2001, Pages 237-245

  Lee, Seung Tae ^a   Jang, Joon Ho ^a   Suh, Hyung Chan ^a   Hahn, Jee Sook ^a   Ko, Yun Woong ^a   Min, Yoo Hong ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Acute myelogenous leukemia; Cytarabineidarubicin; Myelodysplastic syndrome; Salvage chemotherapy; Topotecan

Indexed keywords

CYTARABINE; IDARUBICIN; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG RESPONSE; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; PATIENT SELECTION; PRIORITY JOURNAL; SALVAGE THERAPY; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL RATE; TOPOTECAN; TREATMENT OUTCOME;

EID: 0035196475     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.1188     Document Type: Article

References (39)

1. Treatment of resistant disease
2. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia
3. Bone marrow transplantation for acute myelogeous leukemia: Recent advances
4. High-dose cytosine arabinoside therapy for refractory leukemia
5. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial
6. Impact of reinduction regimens on the clinical course of adult acute nonlymphocytic leukemia
7. Response to salvage therapy and survival after relapse in acute myelogenous leukemia
8. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: A proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy
9. The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period
10. A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia
11. DNA topoisomerase poisons as antitumor drugs
12. DNA topoisomerase I - Targeted chemotherapy of human colon cancer in xenografts
13. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia
14. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia
15. Topotecan in the treatment of hematologic malignancies
16. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia
17. Selected pharmacologic characteristics of idarubicin and idarubicinol
18. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells
19. Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine
20. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia
21. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia
22. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia
23. A phase III trial comparing idarubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group Study
24. Topotecan cytarabine is an active combination regimen in myelodysplastic syndromeschronic myelomonocytic leukemia
25. Treatment of acute myelocytic leukemia: A study by cancerleukemia group B
26. Design analysis of trials of salvage therapy in acute myelogenous leukemia
27. Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome
28. High-dose cytosine arabinoside therapy with without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia
29. High-dose cytosine arabinoside m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia
30. Phase study of mitoxantrone II cytarabine in acute myeloid leukemia
31. High doses of ara-C m-AMSA in the treatment of refractory acute nonlymphocytic leukemia
32. Idarubicin in combination with intermediate-dose cytarabine VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia
33. Mitoxantrone, etoposide, and intermediate-dose cytarabine: An effective tolerable regimen for the treatment of refractory acute myeloid leukemia
34. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes acute myeloid leukemia
35. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML
36. New agents for the treatment of acute myelogenous leukemia: Focus on topotecan retinoids
37. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes chronic myelomonocytic leukemia
38. Idarubicin intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia
39. Cyclophosphamide, ara-C topotecan (CAT) for patients with refractory or relapsed acute leukemia